84610 Federal Register / Vol. 89, No. 205 / Wednesday, October 23, 2024 / Notices 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Government Owned Inventions 

Available for Licensing/Collaboration: 

Tixocortol for the Prevention or 

Treatment of SARS–CoV–2 and Other 

Coronaviruses 

AGENCY: National Institutes of Health, 

HHS. 

ACTION: Notice. 

SUMMARY: The National Cancer Institute 

(NCI), an institute of the National 

Institutes of Health (NIH), Department 

of Health and Human Services (HHS), is 

giving notice of the licensing and 

collaboration opportunity for the 

inventions listed below, which are 

owned by an agency of the U.S. 

Government and are available for 

licensing in the U.S. to achieve 

expeditious commercialization of 

results of federally-funded research and 

development. 

FOR FURTHER INFORMATION CONTACT: 

Inquiries related to this licensing/ 

collaboration opportunity should be 

directed to: Suna Gulay French, Ph.D., 

Technology Transfer Manager, NCI, 

Technology Transfer Center, Email: 

suna.gulay@nih.gov or Phone: 240–276– 

7424. 

SUPPLEMENTARY INFORMATION: The recent 

COVID–19 pandemic led to millions of 

deaths worldwide—presenting an 

urgent need to develop vaccines and 

therapeutics against SARS–CoV–2 

infections. Although vaccines saved 

lives by preventing severe disease 

progression, there remains a need for 

additional therapeutics that may 

prevent and/or treat coronavirus 

infections. The return of symptoms after 

the use of certain COVID–19 

medications demonstrate the need for 

additional treatment options. 

Investigators at the NCI have found a 

previously approved corticosteroid, 

tixocortol, to be an inhibitor of the 

homodimeric main protease (Mpro) of 

SARS–CoV–2 at an allosteric site of 

inhibition, cysteine residue 300 

(Cys300). Coronaviruses rely on Mpro 

for proteolytic processing to produce 

mature forms of the virus—deeming 

Mpro an excellent target to inhibit 

SARS–CoV–2 infection. Tixocortol may 

also be useful against SARS–CoV–1 due 

to the conservation of Cys300 and in 

future coronavirus outbreaks. Tixocortol 

displays inhibitory effect against Mpro 

when added to cell culture up to 18 

hours prior to coronavirus infection, 

indicating possible preventive use. 

Tixocortol pivalate was previously 

manufactured as a spray and would be 

easy to apply before entering crowded 

areas for prevention. 

This Notice is in accordance with 35 

U.S.C. 209 and 37 CFR part 404. 

NIH Reference Number: E–228–2023– 

0. 

Potential Commercial Applications: 

• Treatment of SARS–CoV–2 and 

SARS–CoV–1 infections 

• Preventive of SARS–CoV–2 and 

SARS–CoV–1 infections and 

symptoms 

• Therapeutic and preventive use 

against other coronaviruses and 

respiratory viruses where the 

allosteric site of inhibition is 

conserved. 

Competitive Advantages: 

• Previously developed corticosteroid 

with a good safety profile 

• Non-toxic and nonimmunosuppressive 

• Nasal delivery 

• Potential use against other 

coronaviruses 

• Inhibitory effect against SARS–CoV–2 

main protease in cell culture up to 18 

hours prior to viral infection 

Patent Status: US Provisional 

Application 65/599,446 filed on 

November 15, 2023. 

Therapeutic Area(s): Infectious 

Diseases, immune, or inflammation. 

Development Stage: Discovery. 


khammond on DSKJM1Z7X2PROD with NOTICES
Federal Register / Vol. 89, No. 205 / Wednesday, October 23, 2024 / Notices 84611 

Dated: October 18, 2024. 

Richard U. Rodriguez, 

Associate Director, Technology Transfer 

Center, National Cancer Institute. 

[FR Doc. 2024–24565 Filed 10–22–24; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of Allergy and 

Infectious Diseases; Notice of Closed 

Meeting 

Pursuant to section 1009 of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute of 

Allergy and Infectious Diseases Special 

Emphasis Panel; Interaction between ARVs 

and Hormones in HIV and Coinfections (R01 

Clinical Trial Optional). 

Date: November 19, 2024. 

Time: 10:30 a.m. to 6:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institute of Allergy and 

Infectious Diseases, National Institutes of 

Health, 5601 Fishers Lane, Room 3G34, 

Rockville, MD 20892 (Video Assisted 

Meeting). 

Contact Person: Vishakha Sharma, Ph.D., 

Scientific Review Officer, Scientific Review 

Program, Division of Extramural Activities, 

National Institute of Allergy and Infectious 

Diseases, National Institutes of Health, 5601 

Fishers Lane, Room 3G34, Rockville, MD 

20892, 301–761–7036, vishakha.sharma@

nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.855, Allergy, Immunology, 

and Transplantation Research; 93.856, 

Microbiology and Infectious Diseases 

Research, National Institutes of Health, HHS) 

Dated: October 18, 2024. 

Lauren A. Fleck, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2024–24542 Filed 10–22–24; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HOMELAND 

SECURITY 

Transportation Security Administration 

[Docket No. TSA–2018–0001] 

Surface Transportation Security 

Advisory Committee; Meeting 

AGENCY: Transportation Security 

Administration, Department of 

Homeland Security. 

ACTION: Committee management; Notice 

of open Federal advisory committee 

meeting. 

SUMMARY: The Transportation Security 

Administration (TSA) will hold a 

meeting of the Surface Transportation 

Security Advisory Committee (STSAC) 

on November 21, 2024. Members of the 

public will be able to participate 

virtually via Microsoft Teams. The 


khammond on DSKJM1Z7X2PROD with NOTICESEN23OC24.006</GPH>

Tixocortol Pivala:~g 

Potentially repurpoJ~d 

forSARS-Co 

SARS-COV•2 

Tixocortol Pivalate 

Prodrug 

0 

OH 0 ~OHO C OH HS H e S-S . HI 

l H . i 

-'"+~ I•, o 

0 

Tixocortol Tixocortol dfsulp hide